By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Visterra, Inc. 

One Kendall Square
Suite B3301
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-498-1070 Fax: 617-498-1073


SEARCH JOBS


Industry
Biotechnology






Company News
Visterra, Inc. To Present At The 32nd Annual J.P. Morgan Healthcare Conference 1/13/2014 7:15:21 AM
Visterra, Inc. Acquires Exclusive Patent License For Monoclonal Antibodies Against Dengue Virus From Massachusetts Institute of Technology (MIT) 12/2/2013 9:21:39 AM
Visterra, Inc. Adds $8 Million, Ex-AMAG Pharmaceuticals, Inc. (AMAG) Execs, To Begin Clinical Push For Flu Antibody 12/2/2013 8:49:07 AM
Visterra, Inc. Announces an Oral Presentation of VIS410 Data that Showed Neutralization of H5 and H7 Influenza Strains With Pandemic Potential 9/13/2013 9:32:36 AM
Visterra, Inc. Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains With Pandemic Potential 9/9/2013 10:21:17 AM
Brian Pereira, M.D. is Named New CEO at Visterra, Inc. 7/15/2013 7:32:48 AM
Visterra, Inc. Boosts Series A to $26 Million, Adds Bill & Melinda Gates Foundation as Investor 11/9/2012 6:32:45 AM
Visterra, Inc. Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against the H5N1 (Avian Flu) Influenza Strain in Hanoi, Viet Nam 10/29/2012 6:57:38 AM
Visterra, Inc. Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza With VIS410, a Novel Engineered Human Antibody 9/11/2012 10:07:32 AM
//-->